Asset
Tacabrutideg
BeOne Medicines Ltd. American Depositary Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06970743 | phase3 | active_not_recruiting | 2025-05-29 | 2029-11-30 | BeOne Medicines | A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors |
| NCT07005713 | phase1 | completed | 2025-07-19 | 2026-04-16 | BeiGene | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of BGB-16673 in Adults With Chronic Spontaneous Urticaria |
| NCT06906809 | phase1 | completed | 2025-04-03 | 2025-10-13 | BeiGene | Effect of Phenytoin or Itraconazole on How BGB-16673 is Absorbed and Removed From the Body in Healthy Participants |
| NCT05294731 | phase1_2 | recruiting | 2022-05-06 | 2029-01-31 | BeiGene | Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader |
FDA applications (0)
This company has no applications containing this asset.